Trial reportJAMA ophthalmology2013
Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
Trial report in JAMA ophthalmology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00792922 (Research to Programs for Trachoma Elimination), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Research to Programs for Trachoma Elimination: Antibiotic Trial
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antibiotics for trachoma.The Cochrane database of systematic reviews · 2019Pooled it
- Genomic investigation of Staphylococcus aureus recovered from Gambian women and newborns following an oral dose of intra-partum azithromycin.The Journal of antimicrobial chemotherapy · 2019Trial
- Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities.Ophthalmic epidemiology · 2019Trial
- Long-term Impact of Oral Azithromycin Taken by Gambian Women During Labor on Prevalence and Antibiotic Susceptibility of Streptococcus pneumoniae and Staphylococcus aureus in Their Infants: Follow-up of a Randomized Clinical Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Trial
- Comparison of Mass Azithromycin Coverage Targets of Children in Niger: A Cluster-Randomized Trachoma Trial.The American journal of tropical medicine and hygiene · 2018Trial
- Comparison of Methods for Assessing Chlamydia trachomatis Transmission Intensity: A Systematic Review.The American journal of tropical medicine and hygiene · 2026Article
- Transparent reporting of recruitment and informed consent approaches in clinical trials recruiting children with minor parents in sub-Saharan Africa: a secondary analysis based on a systematic review.BMC public health · 2021Article
- Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial.The British journal of ophthalmology · 2018Article
- Clinical signs of trachoma are prevalent among Solomon Islanders who have no persistent markers of prior infection withWellcome open research · 2018Article
- Reduced-cost Chlamydia trachomatis-specific multiplex real-time PCR diagnostic assay evaluated for ocular swabs and use by trachoma research programmes.Journal of microbiological methods · 2017Article
- Low Prevalence of Conjunctival Infection with Chlamydia trachomatis in a Treatment-Naïve Trachoma-Endemic Region of the Solomon Islands.PLoS neglected tropical diseases · 2016Article
- Mass drug administration for trachoma: how long is not long enough?PLoS neglected tropical diseases · 2015Article
- Geospatial distribution and clustering of Chlamydia trachomatis in communities undergoing mass azithromycin treatment.Investigative ophthalmology & visual science · 2014Article
- The limits of medical interventions for the elimination of preventable blindness.Tropical medicine and health · 2014Article
- Will the SAFE strategy be sufficient to eliminate trachoma by 2020? Puzzlements and possible solutions.TheScientificWorldJournal · 2013Review
- Development and deployment of a smartphone application for diagnosing trachoma: Leveraging code-free deep learning and edge artificial intelligence.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
importanceThe World Health Organization recommends at least 3 annual mass drug administrations (MDAs) of azithromycin in places where the prevalence of follicular trachoma (FT) is greater than 10%. However, stopping MDA prior to 3 rounds, if monitoring indicates an absence of infection with Chlamydia trachomatis even if FT persists, may be more cost-effective.
objectiveTo determine the prevalence of infection in communities randomized to 3 rounds of annual MDAs with azithromycin compared with communities randomized to a stopping rule, where MDA could cease if the infection rate was low. DESIGN A 1:1 community randomized trial comparing usual care with a cessation rule. The Partnership for the Rapid Elimination of Trachoma-Ziada Trial was conducted from February 1, 2010, through September 1, 2011.
settingSixteen communities in Tanzania with trachoma prevalence rates between 10% and 20%.
participantsA total of 100 children aged 5 years or younger randomly drawn from each community. Children had to reside in an eligible community, have no ocular condition that prevented trachoma grading or ocular specimen collection, and have a guardian who could provide consent for participation.
interventionsCessation of MDA with azithromycin if the community had no infection in their sample at 6 months or 18 months.
main outcome measureThe prevalence of C trachomatis at 18 months.
resultsNone of the intervention communities met criteria to stop MDA based on the 6-month or 18-month survey; all, as well as the usual care communities, were scheduled for a third MDA round. There was no difference in infection (2.9% vs 4.7%; P = .25) between the usual care and cessation rule communities at 18 months. CONCLUSIONS AND RELEVANCE: In this setting, communities with low (10%-20%) initial prevalence of active trachoma did not have MDA stopped before 3 annual rounds on the basis of monitoring for infection. Infection with C trachomatis in communities with average trachoma rates at 12% to 13% cannot be eliminated before 3 rounds of MDA with azithromycin.
trial registrationclinicaltrials.gov Identifier: NCT00792922.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.